{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:08:48Z","timestamp":1794438528464,"version":"4.9.1"},"reference-count":42,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>In 2016, WHO member states at the World Health Assembly adopted a Global Health Sector Strategy that included a policy of eliminating viral hepatitis. Clear targets were established to assist in achieving this by 2030. The strategy, while achievable, has exposed existing global disparities in healthcare systems and their ability to implement such policies. Compounding this, the regions with most disparity are also those where the hepatitis B prevalence and disease burden are the greatest. Foundational to hepatitis B elimination is the identification of both those with chronic infection and crucially pregnant women, and primary prevention through vaccination. Vaccination, including the birth dose and full three-dose coverage, is key, but complete mother-to-child transmission prevention includes reducing the maternal hepatitis B viral load in the third trimester where appropriate. Innovations and simplified tools exist in order to achieve elimination, but what is desperately required is the will to implement these strategies through the support of appropriate investment and funding. Without this, disparities will continue.<\/jats:p>","DOI":"10.3390\/v14010082","type":"journal-article","created":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T23:35:09Z","timestamp":1641771309000},"page":"82","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Global Disparities in Hepatitis B Elimination\u2014A Focus on Africa"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7128-8329","authenticated-orcid":false,"given":"Mark W.","family":"Sonderup","sequence":"first","affiliation":[{"name":"Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town 7925, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Wendy","family":"Spearman","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town 7925, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"ref_1","unstructured":"WHO (2021). Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, World Health Organization."},{"key":"ref_2","unstructured":"WHO (2021, December 21). Viral Hepatitis Scorecard. Available online: https:\/\/www.afro.who.int\/publications\/hepatitis-scorecard-who-africa-region-implementing-hepatitis-elimination-strategy."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1038\/s41467-021-26475-6","article-title":"The impact of the timely birth dose vaccine on the global elimination of hepatitis B","volume":"12","author":"Nayagam","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_4","unstructured":"WHO (2016). WHO Global Health Sector Strategy on Viral Hepatitis 2016\u20132021, WHO."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jvh.13412","article-title":"The case for simplifying and using absolute targets for viral hepatitis elimination goals","volume":"28","author":"Collaborators","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/ije\/dyaa253","article-title":"The global burden of chronic hepatitis B virus infection: Comparison of country-level prevalence estimates from four research groups","volume":"50","author":"Schmit","year":"2020","journal-title":"Int. J. Epidemiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study","volume":"3","author":"Gamkrelidze","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/0264-410X(90)90209-5","article-title":"Hepatitis B: Global importance and need for control","volume":"8","author":"Maynard","year":"1990","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0168-8278(01)00064-2","article-title":"Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis","volume":"35","author":"Dumpis","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jcv.2014.05.018","article-title":"Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa","volume":"61","author":"Matthews","year":"2014","journal-title":"J. Clin. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e69430","DOI":"10.1371\/journal.pone.0069430","article-title":"Association of early age at establishment of chronic hepatitis B infection with persistent viral replication, liver cirrhosis and hepatocellular carcinoma: A systematic review","volume":"8","author":"Shimakawa","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1136\/gutjnl-2015-309892","article-title":"Natural history of chronic HBV infection in West Africa: A longitudinal population-based study from The Gambia","volume":"65","author":"Shimakawa","year":"2016","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hep.1840010502","article-title":"A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): A final report","volume":"1","author":"Szmuness","year":"1981","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.11604\/pamj.supp.2017.27.3.11981","article-title":"The status of hepatitis B control in the African region","volume":"27","author":"Breakwell","year":"2017","journal-title":"Pan Afr. Med. J."},{"key":"ref_16","unstructured":"(2021, November 28). Hepatitis B Vaccination Coverage [Internet]. Available online: https:\/\/immunizationdata.who.int\/pages\/coverage\/hepb.html?GROUP=WHO%20Regions&ANTIGEN=&YEAR=&CODE=."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/infdis\/jiy028","article-title":"Call to Action: Prevention of Mother-to-Child Transmission of Hepatitis B in Africa","volume":"217","author":"Wilson","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Moturi, E., Tevi-Benissan, C., Hagan, J.E., Shendale, S., Mayenga, D., Murokora, D., Patel, M., Hennessey, K., and Mihigo, R. (2018). Implementing a Birth Dose of Hepatitis B Vaccine in Africa: Findings from Assessments in 5 Countries. J. Immunol. Sci., 31\u201340.","DOI":"10.29245\/2578-3009\/2018\/si.1104"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e004275","DOI":"10.1136\/bmjgh-2020-004275","article-title":"The global impact of the COVID-19 pandemic on the prevention, diagnosis and treatment of hepatitis B virus (HBV) infection","volume":"6","author":"Pley","year":"2021","journal-title":"BMJ Glob. Health"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0264-410X(99)00242-X","article-title":"At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain","volume":"18","author":"Otto","year":"1999","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e931","DOI":"10.1016\/S2214-109X(20)30231-X","article-title":"Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: A modelling and cost-optimisation study","volume":"8","author":"Seaman","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40249-019-0526-8","article-title":"Gender development and hepatitis B and C infections among pregnant women in Africa: A systematic review and meta-analysis","volume":"8","author":"Bigna","year":"2019","journal-title":"Infec. Dis. Poverty"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S2468-1253(17)30295-9","article-title":"Hepatitis B in sub-Saharan Africa: Strategies to achieve the 2030 elimination targets","volume":"2","author":"Spearman","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_24","unstructured":"WHO (2020). Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy, WHO."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","article-title":"Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: A systematic review and meta-analysis","volume":"21","author":"Funk","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2471\/BLT.20.272559","article-title":"Eliminating mother-to-child transmission of human immunodeficiency virus, syphilis and hepatitis B in sub-Saharan Africa","volume":"99","author":"Cohn","year":"2021","journal-title":"Bull. World Health Organ."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2471\/BLT.14.139626","article-title":"Integrated prevention of mother-to-child transmission for human immunodeficiency virus, syphilis and hepatitis B virus in China","volume":"93","author":"Wang","year":"2014","journal-title":"Bull. World Health Organ."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ije\/dyz037","article-title":"Integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis is highly effective and cost-effective: An economic evaluation","volume":"48","author":"Zhang","year":"2019","journal-title":"Int. J. Epidemiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/jvh.13247","article-title":"Hepatitis B in sub-Saharan Africa-How many patients need therapy?","volume":"27","author":"Sonderup","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_30","unstructured":"WHO (2015). Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, WHO."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jhep.2019.01.037","article-title":"The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia","volume":"70","author":"Aberra","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2019.03.009","article-title":"An appraisal of the WHO hepatitis B treatment guidelines applicability to Africans","volume":"70","author":"Dusheiko","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/liv.13393","article-title":"Are non-invasive fibrosis markers for chronic hepatitis B reliable in sub-Saharan Africa?","volume":"37","author":"Desalegn","year":"2017","journal-title":"Liver Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jhep.2019.03.011","article-title":"Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa","volume":"70","author":"Umutesi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_35","first-page":"1442","article-title":"Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa","volume":"70","author":"Shimakawa","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/jvh.13489","article-title":"Analytical validation of hepatitis B core-related antigen (HBcrAg) using dried blood spots (DBS)","volume":"28","author":"Shimakawa","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.16258","article-title":"Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis","volume":"53","author":"Brunetto","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cgh.2020.04.045","article-title":"Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants","volume":"19","author":"Yoshida","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1128\/JCM.02980-14","article-title":"Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa","volume":"53","author":"Njai","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1016\/S2214-109X(16)30130-9","article-title":"Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: The Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study","volume":"4","author":"Lemoine","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_42","unstructured":"(2019, July 02). Afican Union Cairo Declaration on Viral Hepatitis in Africa. Available online: https:\/\/au.int\/sites\/default\/files\/newsevents\/workingdocuments\/36768-wd-sa24616_e_original_declaration_on_viral_hepatitis.pdf."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/1\/82\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:00:01Z","timestamp":1760364001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/1\/82"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["v14010082"],"URL":"https:\/\/doi.org\/10.3390\/v14010082","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]}}}